Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts - 07/09/11
Background: |
Contact immunotherapy has been shown to be effective for warts. Two previous studies on the use of squaric acid dibutylester (SADBE) for warts have reported widely divergent cure rates (10% and 60%).
Objective: |
Our purpose was to determine the efficacy of SADBE in the treatment of recalcitrant warts.
Methods: |
We treated 29 patients with SADBE for warts that were resistant to other therapies. The patient population had warts for a mean duration of 2.1 years. Patients were sensitized with 1% or 2% SADBE in acetone under occlusion, the treated with 0.5% to 5% SADBE applied to their warts every 2 to 4 weeks in the office.
Results: |
Clearing of all warts was seen in 20 of 29 patients (69%), improvement in 3 patients (10%), and no change in 6 patients (21%). For the cured patients, mean duration of treatment was 4.2 months (range, 1 to 12 months) and mean number of treatments was 5.7 (range, 2 to 15). Adverse effects included acute contact dermatitis with 6 patients experiencing blisters and one experiencing hypopigmentation.
Conclusion: |
SADBE treatment is worth considering in patients with recalcitrant warts, especially in those who tolerate painful procedures poorly.
Le texte complet de cet article est disponible en PDF.Vol 41 - N° 4
P. 595-599 - octobre 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?